Tessier-Lavigne leaves Pfizer board for Denali post
Tessier-Lavigne chose to leave the board at the same time that Denali, a biotechnology company that specializes in creating effective therapies to treat neurodegenerative diseases, was launched. Because Tessier-Lavigne is the co-founder of the new biotechnology company, he is leaving the Pfizer board to chair Denali.
“We’d like to thank Dr. Tessier-Lavigne for his service on Pfizer’s board, particularly for his expertise and counsel in scientific matters,” Pfizer Chairman and Chief Executive Officer Ian Read said. “While we regret the loss of Marc’s service, we congratulate him on the launch of Denali and offer him our best wishes for all of his future endeavors.”
Tessier-Lavigne began serving on Pfizer’s board of directors in December 2011. Most recently, he was a member of the Regulatory and Compliance Committee as well as the Science and Technology Committee.
“I want to thank Pfizer for the opportunity to serve on its board of directors,” Tessier-Lavigne said. “Pfizer is an outstanding company, and I wish it continued success.”